explore -WSS

explore

author：fashion 2025-09-27 09:46:24 - browse：51523

James Comer -- coverage from STAT — Rep. James Comer, chair of the House Oversight Committee Kevin Dietsch/Getty Images

WASHINGTON — Congress wants to reform PBM business practices to help lower the cost of medicines — but don’t think they’ve forgotten drugmakers have a role in high drug prices.

Two lawmakers, including a Republican, questioned PhRMA Chief Operating Officer Lori Reilly about just how much her group was spending on its major campaigns against PBMs this year. Both Reps. Summer Lee (D-Pa.) and Eric Burlison (R-Mo.) used their time to question drugmakers over their spending on lawsuits against Medicare drug price negotiation and ad campaigns against pharmacy benefit managers.

Although Lee started off bashing PBMs for the fees they charge drugmakers, she quickly aimed her fire back on pharma. She said brand drugmakers charge Americans double what they charge other countries, and she asked why several drugmakers are suing the federal government over Medicare’s drug price negotiation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Vaccine advisory panel ACIP left half staffed by HHS

WSS

Why did Pfizer dish out millions for a Super Bowl ad?

Mitch McConnell episode has important public health takeaway

For Medicare Advantage, Democrats want stronger protections around AI

5 important ways Henrietta Lacks changed medical science

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Private equity deals in Medicare Advantage declines

hotspot

explore

hotspot

Walensky prepares to leave CDC — and Congress — behind

Private equity deals in Medicare Advantage declines

Heart attack and stroke risk calculators need revising

The dental labor crisis is a moment of opportunity

Guidelines to prevent youth baseball injuries need more muscle

‘Oppenheimer’ and the risks of AI in health care

Wildfire smoke exposes gaps in outdoor worker protections

What the US credit downgrade means for the economy, your finances

After affirmative action ruling, medical educators look to 'holistic review'

Medicare threatens to cut off funding for HCA's Mission hospital

leisure time

KalVista pill reduced swelling 'attacks' caused by genetic disease

Gilead might be held responsible for not developing a drug

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Medical mystery: When a cough is not just a cough

Private equity deals in Medicare Advantage declines

Medicare Advantage proposed rates disappoint insurers

knowledge

focus

explore

explore